Lupin: Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which…
Lupin (LUPIN) filed a disclosure titled "Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which MPPI has become a step-down wholly owned subsidiary of the Company…". The company is valued at about ₹92,827…
What happened
Lupin (LUPIN) filed a disclosure with the exchanges on 1 October 2026 at 10:09 AM titled "Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed buyback of 30,559 shares, pursuant to which MPPI has become a step-down wholly owned subsidiary of the Company…".
Company snapshot
Lupin is a mid-cap company in the Healthcare sector, with a market value of about ₹92,827 crore.
The stock last traded at ₹2,030.2, against a 52-week range of ₹1,900–₹2,529.5 (19.7% below the high).
Before this filing the shares had moved −5.7% over the month and −18.0% over three months. Average daily turnover over the last 20 sessions was about ₹136 crore.
Promoters held 46.85% at the end of Q1 FY27. Foreign institutions owned 22.42% and domestic institutions 24.65%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,268 | 1,219 | 26.7 |
| Q2 FY26 | 7,048 | 1,477.9 | 32.36 |
| Q3 FY26 | 7,168 | 1,175.6 | 25.74 |
| Q4 FY26 | 7,475 | 1,460.3 | 31.96 |
| Q1 FY27 | 8,277 | 1,415 | 30.95 |
What history shows
BCEIE's records show 4 previous m&a filings from the company since May 2026.
After those filings, the stock fell 0.1% on average the next trading day and was up 0.2% on average after five days (3 filings with price data).
Across 113 similar disclosures by other Healthcare companies, shares moved +0.7% on average the next day and +1.0% over five days; 63% of them rose the next day.
Market-wide, 1,931 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 21 Jul 2026 | M&A | −2.9% | −3.3% |
| 1 Jul 2026 | M&A | +3.3% | +4.4% |
| 29 May 2026 | M&A | −0.8% | −0.6% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
- Lupin share price is currently 'overemphasizing' a risk while 'undermining' a positive, HSBC says
- Lupin Limited (LUPIN.NS) Stock Price, News, Quote & History
- Lupin Share Price Rises 2.52%: Price, Valuation, Peer View
- Dr. Reddy’s, Lupin shares among buzzing stocks as pharma sector back in focus
- Alembic Pharmaceuticals vs Lupin vs FDC Limited: Comparison
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.